28028
Pedro Marques da Silva, Carlos Aguiar
62. Bangalore S, Fayyad R, Hovingh GK, et al. Treating to New Targets Steering Committee and
Investigators. Statin and the risk of renal-related serious adverse events: Analysis from the
IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. Am J Cardiol.
2014; 113: 2018-20.
63. Rojas-Fernandez CH, Goldstein LB, Levey AI, et al. , The National Lipid Association’s Safety
Task Force. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin
Lipidol. 2014; 8 (3 Suppl): S5-16.
64. Rojas-Fernandez C, Hudani Z, Bittner V. Statins and cognitive side effects: what cardiologists
need to know. Cardiol Clin. 2015; 33: 245-56.
65. Argov Z. Statins and the neuromuscular system: a neurologist’s perspective. Eur J Neurol.
2015; 22: 31-6.
66. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update.
Vasc Health Risk Manag. 2012;.8:.415-27.
67. Kones R, Rumana U. Current treatment of dyslipidemia: evolving roles of non-statin and
newer drugs. Drugs. 2015; 75: 1201-28.
68. Stitziel NO, Won HH, Morrison AC, et al. Inactivating mutations in NPC1L1 and protection
from coronary heart disease. Myocardial Infarction Genetics Consortium Investigators N
Engl J Med. 2014; 371: 2072-82.
69. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower
low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by poly-
morphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J
Am Coll Cardiol. 2015; 65: 1552-61.
70. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to
Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372: 2387-97.
71. Rosenson RS. Lipid lowering with fibric acid derivatives. UpToDate. 2015.
-
date.com/contents/lipid-lowering-with-fibric-acid-derivatives?source=search_result&sear-
ch=fibrates&selectedTitle=1~140.
72. Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group Effects of combination lipid
therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-74.
73. Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascu-
lar risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meet-
ing on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015; 19: 1-12.
